Effective gene therapy with nonintegrating lentiviral vectors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis. This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction. With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NILVs encoding for in vivo expression of GFP have been reported in organs such as the brain, liver, and spinal cord via stable gene transfer for longer periods (up to months) in several studies [22,73,131,132,133,134].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [22]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [49]
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Class I integration-deficient lentiviral vectors have been reported to be inefficient for transduction of dividing cells in vitro”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“We produced paired integration-proficient and integration-deficient HIV-1 vectors using self-inactivating system”
MethodNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“In contrast, direct administration of nonintegrating vectors based on human immunodeficiency virus (HIV) or feline immunodeficiency virus (FIV) has not previously resulted in significant expression in vivo”
BackgroundA quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“We carried out qPCR titrations of total vector DNA according to a published protocol for late reverse transcriptase amplicon quantificatio”
MethodMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“We designed three different LAM-PCR reactions to scan vector regions downstream of the 5¢-dLTR (1), upstream of the 3¢-dLTR (2) and downstream of residual env sequences (a region including cPPT/CTS and internal promoter, 3) for integration junctions.”
MethodSelf-citationDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationSide effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2988 · Cited by 386
Shank, P. R., Hughes, S. H., Kung, H.-J., Majors, J. E., Quintrell, N., Guntaka, R. V., Bishop, J. M., & Varmus, H. E. (1978) · Cell · doi:10.1016/0092-8674(78)90063-6 · Cited by 383
Cited by
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“These approaches would allow the transduction of BDNF in a cell-specific and inducible manner (57, 650).”
BackgroundLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845
Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673
“Discussion Clinical trials of uniocular subretinal gene therapy in patients with RPE65-LCA were initiated after proof-of-concept studies using subretinal delivery of vector gene showed restored vision in Rpe65-deficient dogs (4, 5, 8, 11, 12) and mice (2, 6, 7, 9, 10, 13, 29, 30).”
BackgroundViral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
Gene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
“Most recently, however, two groups employed packaging cassettes harboring distinct mutations to demonstrate efficient in vivo transgene delivery in ocular and brain tissues [76, 77].”
BackgroundRecent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
“Then, the lentivector DNA remains in the nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as retina, brain, and muscle (Apolonia et al. 2007; Philippe et al. 2006; Yanez-Munoz et al. 2006).”
Lentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
Reconstitution of an Infectious Human Endogenous Retrovirus
Lee, Y. N., & Bieniasz, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030010 · Cited by 311
“In some cases, low levels of reporter gene expression mediated by retroviral gene transfer can be mediated by reverse-transcribed but nonintegrated retroviral DNA, which can exist as linear or circular forms in target cells [32–34].”
GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons
English, D. F., Ibanez-Sandoval, O., Stark, E., Tecuapetla, F., Buzsáki, G., Deisseroth, K., Tepper, J. M., & Koos, T. (2012) · Nature Neuroscience · doi:10.1038/nn.2984 · Cited by 292
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Human Studies of Angiogenic Gene Therapy
Gupta, R., Tongers, J., & Losordo, D. W. (2009) · Circulation Research · doi:10.1161/circresaha.109.200386 · Cited by 276
Meganucleases and DNA Double-Strand Break-Induced Recombination: Perspectives for Gene Therapy
Paques, F., & Duchateau, P. (2007) · Current Gene Therapy · doi:10.2174/156652307779940216 · Cited by 273
“Today, the major trend is towards novel viral vectors that would bypass the risks of insertional mutations, with two major (non mutually exclusive) families: non integrative vectors [Yanez-Munoz et al., 2006] and vectors devoid of “at risk” enhancer or promoter sequences, or with such sequences tamed by “insulators” […”
BackgroundLeber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
“Gene therapy efficiency of an integration-deficient lentiviral vector carrying human RPE65 transgene with various promoters was evaluated in Rpe65rd12 mice (Yanez-Munoz et al., 2006).”
BackgroundA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249
Biology and therapy of inherited retinal degenerative disease: insights from mouse models
Veleri, S., Lazar, C. H., Chang, B., Sieving, P. A., Banin, E., & Swaroop, A. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017913 · Cited by 231
“Lenti- and adenovirus-based vectors are also being investigated for gene delivery to the retina (Yáñez-Muñoz et al., 2006), but these do not seem to be very efficient in transducing photoreceptors (Puppo et al., 2014).”
BackgroundIntegration-deficient Lentiviral Vectors: A Slow Coming of Age
Wanisch, K., & Yáñez-Muñoz, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.122 · Cited by 222
Self-citationKong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
“Additionally, nonintegrating vectors have been developed and shown to facilitate efficient sustained transgene expression in RPE for 8 weeks in a rodent model (49).”
BackgroundNew Avenues for the Treatment of Huntington’s Disease
Kim, A., Lalonde, K., Truesdell, A., Gomes Welter, P., Brocardo, P. S., Rosenstock, T. R., & Gil-Mohapel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168363 · Cited by 191
“To overcome these problems, new adeno-associated viral vectors lacking pathogenicity and immunogenicity as well as nontoxic viral systems [291,292] are currently being investigated.”
BackgroundVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“Intravitreal delivery of LV vectors typically fails to produce efficient intraocular expression (Bainbridge et al., 2001; Greenberg et al., 2007; Yanez-Munoz et al., 2006), however, partial transduction of RPE and neuroretina has been observed near the injection site in some studies (Harvey et al.,…”
BackgroundMethodGoncalves, M. B., Suetterlin, P., Yip, P., Molina-Holgado, F., Walker, D. J., Oudin, M. J., Zentar, M. P., Pollard, S., Yáñez-Muñoz, R. J., Williams, G., et al. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.05.001 · Cited by 177
Self-citationRecombinase-Mediated Cassette Exchange (RMCE): Traditional Concepts and Current Challenges
Turan, S., Galla, M., Ernst, E., Qiao, J., Voelkel, C., Schiedlmeier, B., Zehe, C., & Bode, J. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.004 · Cited by 178
“The system is either based on integrase-deficient gamma-retroviral or lentiviral vectors.(73) Huang et al.”
MethodStable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174
Self-citationAbordo-Adesida, E., Follenzi, A., Barcia, C., Sciascia, S., Castro, M. G., Naldini, L., & Lowenstein, P. R. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.741 · Cited by 170
Molecular Engineering of Viral Gene Delivery Vehicles
Schaffer, D. V., Koerber, J. T., & Lim, K.-I. (2008) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.10.061807.160514 · Cited by 159
The role of unintegrated DNA in HIV infection
Sloan, R. D., & Wainberg, M. A. (2011) · Retrovirology · doi:10.1186/1742-4690-8-52 · Cited by 158
“But it remains to be seen for how long unintegrated DNA might persist in slow or non-dividing cell types in patients receiving integrase inhibitor therapy, given data for infections with integrase defective lentiviral vectors in animal models, it might be anticipated that such a reservoir would be relatively long live…”
BackgroundDong, W., & Kantor, B. (2021) · Viruses · doi:10.3390/v13071288 · Cited by 168
“Notably, even that low level of expression has been found to be sufficient to correct human hereditary diseases [34,35].”
BackgroundGammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 183
“especially in non-dividing cells (such a retina cells) could be demonstrated [136,137].”
BackgroundPreparation for a first-in-man lentivirus trial in patients with cystic fibrosis
Alton, E. W. F. W., Beekman, J. M., Boyd, A. C., Brand, J., Carlon, M. S., Connolly, M. M., Chan, M., Conlon, S., Davidson, H. E., Davies, J. C., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208406 · Cited by 150
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
“For example, Thrasher et al.36 and Suwanmanee et al.37 have successfully employed IDLVs in mouse models as gene replacement therapies for degenerative retinal disease and hemophilia B, respectively.”
BackgroundMátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
“In contrast, IDLVs have been reported to support sustained transgene expression in quiescent mouse tissues, such as the retina and central nervous system, likely because the episomal vector DNA is retained within the postmitotic nucleus.(17,18,20) Despite these advances, the ability of IDLVs to achieve therapeutically…”
BackgroundSelf-citationEmerging restorative treatments for Parkinson's disease
Deierborg, T., Soulet, D., Roybon, L., Hall, V. J., & Brundin, P. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.001 · Cited by 154
Protein transduction from retroviral Gag precursors
Voelkel, C., Galla, M., Maetzig, T., Warlich, E., Kuehle, J., Zychlinski, D., Bode, J., Cantz, T., Schambach, A., & Baum, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914517107 · Cited by 144
“A subset of these proteins forms the reverse transcriptase complex and the preintegration complex to eventually integrate the retroviral genomic DNA into cellular chromosomes (8, 9).”
BackgroundInfluentialHuman macrophages support persistent transcription from unintegrated HIV-1 DNA
Kelly, J., Beddall, M. H., Yu, D., Iyer, S. R., Marsh, J. W., & Wu, Y. (2007) · Virology · doi:10.1016/j.virol.2007.11.007 · Cited by 149
“The ability of unintegrated viral DNA to persist and to transcribe has stimulated a recent interest in using unintegrating lentiviral vector to transduce non-dividing cells, such as ocular or neuronal cells, for gene therapy (Philippe et al., 2006; Saenz et al., 2004; Yanez-Munoz et al., 2006).”
BackgroundApplications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Lundberg, C., Björklund, T., Carlsson, T., Jakobsson, J., Hantraye, P., Déglon, N., & Kirik, D. (2008) · Current Gene Therapy · doi:10.2174/156652308786847996 · Cited by 146
“In this context it is noteworthy that non-integrating lentiviral vectors, which may be considered safer for gene therapy, express transgenes well in the retina [27] and thus represents a possible future venue for gene therapy to the eye.”
BackgroundNovel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer
Vargas, J., Gusella, G. L., Najfeld, V., Klotman, M., & Cara, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959515 · Cited by 143
Integrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
Nonintegrating Gene Therapy Vectors
Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 136
Self-citationHematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease
Kiem, H., Jerome, K. R., Deeks, S. G., & McCune, J. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2011.12.015 · Cited by 134
“Nonintegrating Vector Systems or Transfection Analternative gene transfer approach is to utilize viral vectors that have been modified so they are unable to integrate into the host genome (Yáñez-Muñoz et al., 2006).”
BackgroundEpilepsy Gene Therapy Using an Engineered Potassium Channel
Snowball, A., Chabrol, E., Wykes, R. C., Shekh‐Ahmad, T., Cornford, J. H., Lieb, A., Hughes, M. P., Massaro, G., Rahim, A. A., Hashemi, K. S., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1143-18.2019 · Cited by 129
“The popularity of nonintegrating lentiviruses for therapeutic gene transfer is growing, and the vectors have already demonstrated preclinical efficacy in the treatment of degenerative retinal disease and hemophilia B (Yáñez-Muñoz et al., 2006; Suwanmanee et al., 2014).”
BackgroundMethodInfluentialA new age of precision gene therapy
Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M. A., Trapani, I., & Büning, H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01952-9 · Cited by 145
Viral Vectors and Delivery Strategies for CNS Gene Therapy
Gray, S. J., Woodard, K., & Samulski, R. J. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.50 · Cited by 135
State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 106
“Taking advantage of these episomal circles, IDLV have recently emerged as novel and efficient gene carriers, facilitating high levels of transient expression from linear and circular DNA forms [85-88].”
BackgroundClinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
“IDLVs have been demonstrated to efficiently target the RPE, though there have been too few studies to determine the rate of residual integration, and whether it is lower than with rAAV (Fabes et al., 2006; Wanisch and YanezMunoz, 2009; Yanez-Munoz et al., 2006).”
ResultSelf-citationSinghal, S., Lawrence, J. M., Bhatia, B., Ellis, J. S., Kwan, A., MacNeil, A., Luthert, P. J., Fawcett, J. W., Perez, M.-T., Khaw, P. T., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0898 · Cited by 127
Self-citationBemelmans, A., Kostic, C., Crippa, S. V., Hauswirth, W. W., Lem, J., Munier, F. L., Seeliger, M. W., Wenzel, A., & Arsenijévic, Y. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030347 · Cited by 131
“(2006) demonstrates that an integrationdeficient lentiviral vector is as efficient as an integrationproficient vector for delivery of Rpe65 in another model of LCA, the Rpe65 mouse [40].”
BackgroundNew developments in lentiviral vector design, production and purification
Segura, M. M., Mangion, M., Gaillet, B., & Garnier, A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.779249 · Cited by 133
“The LVV DNA thus remains in the cell nucleus as an episome, leading to sustained expression in post-mitotic cells and tissues such as the retina [69], brain [69,70] and muscle [71].”
BackgroundLentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B
Hashimoto, T., Gibbs, D., Lillo, C., Azarian, S. M., Legacki, E. L., Zhang, X., Yang, X.-J., & Williams, D. S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302897 · Cited by 125
Gene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics
Breckpot, K., Aerts, J. L., & Thielemans, K. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302947 · Cited by 129
Viral complementation allows HIV-1 replication without integration
Gelderblom, H. C., Vatakis, D. N., Burke, S. A., Lawrie, S. D., Bristol, G. C., & Levy, D. N. (2008) · Retrovirology · doi:10.1186/1742-4690-5-60 · Cited by 131
Technological Overview of iPS Induction from Human Adult Somatic Cells
Bayart, É., & Cohen‐Haguenauer, O. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020002 · Cited by 135
Will Nanotechnology Bring New Hope for Gene Delivery?
Wong, J. K. L., Mohseni, R., Hamidieh, A. A., MacLaren, R. E., Habib, N., & Seifalian, A. M. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.12.009 · Cited by 112
Self-citationMethods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
“Nevertheless, even the reduced expression levels of nonintegrating vectors have been shown to be sufficient for correcting genetic disorders in experimental animals (Philippe et al., 2006; Yanez-Munoz et al., 2006).”
BackgroundBaruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 114
“…of the integrase protein to generate non- integrating or integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and…”
BackgroundGene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
“Efficient and sustained transgenic expression was demonstrated in vivo using non-integral lentiviral vectors in post-mitotic tissues, such as RPE, and at levels equivalent to those of their competent counterparts for integration [40].”
BackgroundTargeted Genome Modifications Using Integrase-deficient Lentiviral Vectors
Cornu, T. I., & Cathomen, T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300345 · Cited by 105
Ocular gene delivery using lentiviral vectors
Balaggan, K. S., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.153 · Cited by 113
Self-citationRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Self-citationHyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432591 · Cited by 101
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
Yip, P. K., Wong, L., Sears, T. A., Yáñez‐Muñoz, R. J., & McMahon, S. B. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000399 · Cited by 99
“HIV vector pseudotyped with a VSV-G envelope produced strong expression and anterograde labelling [49].”
Self-citationGene therapy: targeting the myocardium
Lyon, A. R., Sato, M., Hajjar, R. J., Samulski, R. J., & Harding, S. E. (2007) · Heart · doi:10.1136/hrt.2007.116483 · Cited by 112
Hybrid Lentivirus-transposon Vectors with a Random Integration Profile in Human Cells
Staunstrup, N. H., Moldt, B., Mátés, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvák, Z., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.10 · Cited by 96
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 112
A Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94
“Several groups recently demonstrated notable in vitro and in vivo expression from nonintegrating, self-inactivating (SIN) lentiviral vectors [17,18,28,30,34].”
BackgroundResultZhao, R., Muir, E. M., Alves, J. N., Rickman, H. M., Allan, A. Y., Kwok, J. C. F., Roet, K. C. D., Verhaagen, J., Schneider, B. L., Bensadoun, J., et al. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.08.003 · Cited by 100
Self-citationZuccato, C., & Cattaneo, E. F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_14 · Cited by 97
Kane, N. M., Xiao, Q., Baker, A. H., Luo, Z., Xu, Q., & Emanueli, C. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.10.004 · Cited by 94
MicroRNA-based conversion of human fibroblasts into striatal medium spiny neurons
Richner, M., Victor, M. B., Liu, Y., Abernathy, D. G., & Yoo, A. S. J. (2015) · Nature Protocols · doi:10.1038/nprot.2015.102 · Cited by 95
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Zinc finger nuclease technology heralds a new era in mammalian transgenesis
Provost, F. L., Lillico, S. G., Passet, B., Young, R. A., Whitelaw, B., & Vilotte, J.-L. (2009) · Trends in biotechnology · doi:10.1016/j.tibtech.2009.11.007 · Cited by 95
Use of Nonintegrating Lentiviral Vectors for Gene Therapy
Philpott, N. J., & Thrasher, A. J. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.013 · Cited by 101
Self-citationWilliams, M. L., Coleman, J. E., Haire, S. E., Alemán, T. S., Cideciyan, A. V., Sokal, I., Palczewski, K., Jacobson, S. G., & Semple‐Rowland, S. L. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030201 · Cited by 91
Karwacz, K., Mukherjee, S., Apolonia, L., Blundell, M. P., Bouma, G., Escors, D., Collins, M. K., & Thrasher, A. J. (2009) · Journal of Virology · doi:10.1128/jvi.02519-08 · Cited by 87
“These nonintegrating lentivectors have been shown to mediate long-term gene expression in nondividing tissues, such as retina (30), brain (23), and muscle (1).”
BackgroundSelf-citationOptogenetic and chemogenetic therapies for epilepsy
Walker, M. C., & Kullmann, D. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107751 · Cited by 96
State-of-the-art human gene therapy: part I. Gene delivery technologies.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 115
Immunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 93
Llana, O. C., Houghton, B. C., Rinaldi, F., Taylor, H., Yáñez‐Muñoz, R. J., Uney, J. B., Wong, L., & Caldwell, M. A. (2014) · Molecular Therapy · doi:10.1038/mt.2014.206 · Cited by 94
Self-citationSuccessful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84
Moldt, B., Miskey, C., Staunstrup, N. H., Gogol‐Döring, A., Bak, R. O., Sharma, N., Mátés, L., Izsvák, Z., Chen, W., Ivics, Z., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.47 · Cited by 90
Gene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
Prospects for retinal gene replacement therapy
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.02.003 · Cited by 99
Self-citationNew Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment
Riva, A., Golda, A., Balagura, G., Amadori, E., Vari, M. S., Piccolo, G., Iacomino, M., Lattanzi, S., Salpietro, V., Minetti, C., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.753753 · Cited by 92
“However, possible insertional mutagenesis may be reduced by using integration-deficient lentivectors, which simultaneously ensure stable transduction (73).”
BackgroundKlausner, E. A., Peer, D., Chapman, R. L., Multack, R. F., & Andurkar, S. V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.041 · Cited by 80
Howarth, J. L., Lee, Y., & Uney, J. B. (2009) · Cell Biology and Toxicology · doi:10.1007/s10565-009-9139-5 · Cited by 96
“Although such vectors offer a limited expression window in mitotic cells, good expression is produced in post-mitotic cells, such as neurons (Yanez-Munoz et al. 2006).”
BackgroundAmelioration of Psoriasis by Anti-TNF-α RNAi in the Xenograft Transplantation Model
Jakobsen, M., Stenderup, K., Rosada, C., Moldt, B., Kamp, S., Dam, T. N., Jensen, T. G., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.141 · Cited by 76
Kato, S., Kuramochi, M., Takasumi, K., Kobayashi, K., Inoue, K., Takahara, D., Hitoshi, S., Ikenaka, K., Shimada, T., Takada, M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.111 · Cited by 82
Sleeping Beauty Transposition From Nonintegrating Lentivirus
Vink, C. A., Gaspar, H. B., Gabriel, R., Schmidt, M., McIvor, R. S., Thrasher, A. J., & Qasim, W. (2009) · Molecular Therapy · doi:10.1038/mt.2009.94 · Cited by 78
Self-citationClinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
“Lentiviral vectors can engender long-term, stable transgene expression in the CNS, persisting more than 6 months in the rat brain and as long as 12 months in other tissues (Bayer et al., 2008; Kantor et al., 2011; Yanez-Munoz et al., 2006).”
BackgroundHutson, T. H., Verhaagen, J., Yáñez‐Muñoz, R. J., & Moon, L. D. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.71 · Cited by 77
Self-citationNon-Integrating Lentiviral Vectors
Sarkis, C., Philippe, S., Mallet, J. J., & Serguera, C. (2008) · Current Gene Therapy · doi:10.2174/156652308786848012 · Cited by 83
“NIL vectors with a clearly non-integrating phenotype can be obtained by introducing mutations into any of these regions [71-73, 84] (Table 1).”
BackgroundInfluentialDi, W., Larcher, F., Semenova, E., Talbot, G., Harper, J. I., Río, M. D., Thrasher, A. J., & Qasim, W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.201 · Cited by 72
Self-citationLentiviral vectors can be used for full-length dystrophin gene therapy
Counsell, J. R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C. A., Howe, S. J., Waddington, S. N., Thrasher, A. J., Muntoni, F., Morgan, J. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00152-5 · Cited by 75
Self-citationProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70
“undetectable levels, as previously described [20,21], confirming the non integrated status of the vector genome (data not shown).”
BackgroundMethodResult
Metadata
- Authors
- Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., Duran, Y., Bartholomae, C., von Kalle, C., Heckenlively, J. R., Kinnon, C., Ali, R. R., & Thrasher, A. J.
- Affiliations
- University College London (GB)
- University of Freiburg (DE)
- Great Ormond Street Hospital (GB)
- Corresponding author
- Ali, Robin R
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-02-19
- Volume
- 12
- Issue
- 3
- Pages
- 348-353
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2167845957
- Cited by
- 460
- References
- 30
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 8 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 31 · 2013: 27 · 2012: 35
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- University College London
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, retroviral vectors, stable transgene expression, ocular gene therapy, retinal degeneration, postmitotic tissues
- MeSH terms
- Retinoid Isomerohydrolase, Animals, Brain, Carrier Proteins, Electroretinography, Eye Proteins, Female, Genetic Vectors, HeLa Cells, Humans, Pigment Epithelium of Eye, Retina, Tumor Cells, Cultured, Genetic Therapy, Lentivirus, Virus Integration, cis-trans-Isomerases, Green Fluorescent Proteins, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.